|
Advertise About
Live
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%

Zymeworks’ Zanidatamab Wins FDA Approval for Biliary Tract Cancer, Opening $1.2B Market

Health Canada and FDA alignment could fast-track Canadian access to zanidatamab for HER2-positive biliary tract cancer — a rare GI malignancy with virtually no approved targeted therapies until now.

Editorial independence
·
Reviewed by editorial team
·
Sources cited & linked
·
Not investment advice
4 min read
· Editorial Policy
Intel core logo visible through a translucent blue abstract structure
Photo by Brecht Corbeel on Unsplash
Key Takeaways
  • FDA granted full approval to Zymeworks’ zanidatamab for HER2-positive biliary tract cancer on November 12, 2026 — the first bispecific antibody approved in this GI indication.
  • The addressable second-line HER2+ BTC population in the U.S. is roughly 1,800–2,400 patients annually, with peak sales estimates of $400M–$650M USD at full penetration.
  • Zymeworks retains direct U.S. and Canadian commercialization rights, making this an immediate revenue inflection point for the previously pre-revenue Vancouver biotech.
  • Health Canada approval could follow within 6–12 months; a Phase 3 readout in gastroesophageal cancer mid-2027 represents the next major catalyst for long-term thesis validation.

Vancouver-based Zymeworks (TSX: ZYME; NYSE: ZYME) received full FDA approval on November 12, 2026, for zanidatamab (brand name: Ziihera) in adult patients with previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer (BTC). The approval makes zanidatamab the first HER2-targeted bispecific antibody approved for a gastrointestinal indication in the United States, a milestone that sent the stock up 34% in pre-market trading before settling to a 22% gain by midday — pushing ZYME to approximately $18.40 USD ($26.19 CAD at the current 1.4235 rate).

The Indication: Rare, Lethal, and Underserved

Biliary tract cancer — encompassing cholangiocarcinoma and gallbladder cancer — affects roughly 12,000 new patients annually in the United States, with HER2 overexpression or amplification present in an estimated 15–20% of those cases. That narrows the addressable second-line population to approximately 1,800–2,400 patients per year in the U.S. alone. Prior to this approval, oncologists had no approved HER2-directed option for BTC; standard second-line chemotherapy regimens deliver median progression-free survival of under four months. In the pivotal HERIZON-BTC-01 trial, zanidatamab achieved an objective response rate of 41.3%, with a median duration of response of 12.9 months — data that meaningfully exceed the historical benchmark for salvage therapy in this setting.

Commercial Opportunity and Peak Sales Estimates

The global biliary tract cancer therapeutics market is projected to reach approximately $1.2 billion USD by 2030, according to GlobalData estimates, with HER2-targeted agents capturing an outsized share given the lack of competition. Sell-side analysts covering ZYME — including desks at Canaccord Genuity and RBC Capital Markets — have published peak sales estimates for zanidatamab in BTC ranging from $400 million to $650 million USD annually at full penetration, assuming label expansion into first-line and adjuvant settings. Zymeworks retains commercialization rights in the United States and Canada; Jazz Pharmaceuticals holds rights in Europe and other markets under a 2022 licensing deal that included a $325 million USD upfront payment. That deal structure means Zymeworks will book U.S. net product revenue directly — a critical inflection point for a company that had been pre-revenue.

Competitive Landscape

Zanidatamab’s most direct competitor in BTC is trastuzumab deruxtecan (Enhertu; AstraZeneca/Daiichi Sankyo), which is being evaluated in BTC under the DESTINY-PanTumor program but does not yet carry an approved indication in this specific cancer type. Pertuzumab plus trastuzumab combinations have shown modest activity in small studies but have not pursued regulatory pathways in BTC. This leaves zanidatamab with a credible first-mover advantage in a niche but highly penetrable market, where oncology community unmet need is well-documented and treatment guidelines will update rapidly.

Canadian Investor Angle and Long-Term Thesis

For TSX investors, ZYME’s dual listing gives Canadian retail investors direct access without currency conversion friction. Health Canada typically acts within six to twelve months of an FDA approval for oncology drugs supported by the same clinical dataset — meaning Canadian patients could gain access to zanidatamab as early as Q3 2027. The broader XBI biotech ETF gained 0.81% on the day to $156.31, suggesting sector sentiment is constructive, but Zymeworks’ move is company-specific rather than a rising-tide event. The long-term thesis hinges on label expansion: Phase 3 trials in HER2-positive gastroesophageal cancer (HERIZON-GEA-01) are ongoing, and a positive readout there — expected in mid-2027 — would expand the addressable population by roughly 10-fold and validate zanidatamab as a platform asset rather than a single-indication drug. Investors should monitor Q4 2026 earnings carefully for initial launch trajectory data, particularly physician adoption rates and payer coverage decisions in the first 90 days post-launch.

Metric Detail
Drug Zanidatamab (Ziihera)
Indication HER2+ biliary tract cancer (2nd line+)
Regulatory Action FDA Full Approval — Nov. 12, 2026
ZYME Stock Reaction +22% to ~$18.40 USD ($26.19 CAD)
Peak Sales Estimate (BTC) $400M–$650M USD
Global BTC Market (2030E) ~$1.2B USD

James Okonkwo

Boreal Markets Staff

Contributing writer at Boreal Markets.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Boreal Markets and SmallCap Communications Inc. are not registered investment advisers. Always conduct your own due diligence before making investment decisions.

The Boreal Brief

Canadian markets intelligence every morning before the open. Free.